The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe.

Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference.

We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.

We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.

Pharmaceutical

Mundipharma

Marc Princen

Liana Del Medico

Petra Molan

Ajay Varshney

Sarah McLoughlin

Yasemin Okur

Bryan Lea

Etienne Claessens

Arnaud Breabout

Yuri Martina

Lori Reber

Miguel Coego

Birgit Kudlek

Francois Bernard

Javier Alvarado Garcia

Marco Cerato

Hywel Day

Benoit Slavicek

Anna Kjellberg

Philippe Mazas

Neil Trueman

Commercial and Business Development

Leadership Team

Business Strategy and Development

Finance Team

Regulatory and Compliance Team

Technical Operations

Teams at Mundipharma